Bolt Biotherapeutics delays trial data, cuts workforce by half

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. FLG
4. GMAB
5. ACCV
6. SPCX
7. XNCR
8. AZN
9. APO
10. META

Go back to Bolt Biotherapeutics delays trial data, cuts workforce by half

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

October 1, 2025 4:05 PM EDT

Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027

REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and... More